Usage Examples
- The Phase 1 SAD cohort dosed on day 31, once the IND was in effect.
- We are still in Phase 1, so the efficacy question belongs in the Phase 2 protocol.
- Our Phase 1 protocol is an outline, so the escalation rules live in the dosing plan.
What is Phase 1 Clinical Trial?
Phase 1 clinical trials are the first human studies of an investigational drug, designed to characterize metabolism, pharmacologic actions, and dose-related side effects rather than to prove effectiveness, typically enrolling 20 to 80 subjects.
Phase 1 clinical trials exist because preclinical animal data cannot predict how a compound behaves in a human body. 21 CFR 312.21(a) frames Phase 1 as the initial introduction of an investigational new drug into humans, closely monitored, and designed to determine metabolism, pharmacologic actions, and the side effects associated with increasing doses, before anyone asks whether the drug works.
Phase 1 clinical trials cover that initial human introduction plus studies of drug metabolism, structure-activity relationships, mechanism of action, and investigational drugs used as research tools to explore biological phenomena. Phase 1 stops short of controlled efficacy testing; 21 CFR 312.21(a) asks only for enough pharmacokinetic and pharmacological information to design well-controlled Phase 2 studies. Phase 1 drug trials also sit outside ClinicalTrials.gov's mandatory registration scope.
Phase 1 clinical trials run under an IND that takes effect 30 days after FDA receives it, unless FDA authorizes an earlier start. Phase 1 protocols are deliberately thinner than later-phase ones, outlining estimated subject numbers, safety exclusions, and the dosing plan. Once dosing starts, Phase 1 sponsors carry the same IND safety-reporting clock as every other phase: 7 and 15 calendar days.
Not to be confused with
- Phase 2
- Phase 2 runs controlled studies to evaluate effectiveness for a specific indication in patients with the disease. Phase 1 is not designed to establish effectiveness; it gathers early evidence of it only if the data allows.
- First-in-human (FIH) study
- FIH names the single study that puts a compound into people for the first time. Phase 1 is the whole phase, which continues with food-effect, drug-interaction, and mechanism-of-action work long after the FIH study closes out.
- IND
- The IND is the regulatory submission that makes the trial lawful; Phase 1 is the trial itself. One IND stays open across Phase 1, 2, and 3, with each phase adding protocols to the same application.
- Maximum tolerated dose (MTD)
- MTD is an output a Phase 1 dose-escalation produces, not a name for the study. A Phase 1 program can complete without ever reaching an MTD if escalation stops at a target exposure.
Phase 1 obligations sit in 21 CFR Part 312. These are the ones that bind a sponsor before and during first-in-human dosing.
What you must do
- 1Hold first-subject dosing until the IND is in effect, which is 30 days after FDA receives it unless FDA notifies the sponsor earlier that the clinical investigations may begin21 CFR 312.40(b)
- 2Design Phase 1 to determine the drug's metabolism and pharmacologic actions in humans and the side effects associated with increasing doses, and generate pharmacokinetic and pharmacological information sufficient to permit the design of well-controlled, scientifically valid Phase 2 studies21 CFR 312.21(a)
- 3Write the Phase 1 protocol as an outline of the investigation: an estimate of the number of patients, a description of safety exclusions, and a dosing plan covering duration, dose, or the method used to determine dose21 CFR 312.23(a)(6)(i)(b)
- 4Notify FDA of any unexpected fatal or life-threatening suspected adverse reaction no later than 7 calendar days after initial receipt of the information, and report other qualifying reports no later than 15 calendar days after the sponsor determines the information qualifies21 CFR 312.32(c)
- 5Check registration status before assuming a ClinicalTrials.gov duty: an applicable drug clinical trial is one whose Study Phase is other than phase 1, so phase 1 drug trials fall outside the mandatory registration requirement42 CFR 11.22
Common mistakes
Treating day 31 as a guaranteed green light
The IND goes into effect 30 days after FDA receives it only if FDA has not placed the investigations on clinical hold (21 CFR 312.40(b)). Teams that lock site activation, drug shipment, and volunteer recruitment against day 31 as a certainty eat the full cost of the slip when a hold letter lands instead.
Reading "20 to 80" as a cap
21 CFR 312.21(a) says the total number of subjects and patients varies with the drug and is generally in the range of 20 to 80. That is descriptive, not a ceiling. Trimming cohorts to stay under 80 buys nothing regulatorily and costs the dose-response characterization that Phase 2 design depends on.
Assuming a small Phase 1 study earns relief from IND safety reporting
21 CFR 312.32(c) sets one clock for every phase: 7 calendar days for unexpected fatal or life-threatening suspected adverse reactions, 15 for the rest. First-in-human is precisely where unexpected events are most likely, and a late report is a finding against the sponsor, not the site.
When This Matters
- The Phase 1 SAD cohort dosed on day 31, once the IND was in effect.
- We are still in Phase 1, so the efficacy question belongs in the Phase 2 protocol.
- Our Phase 1 protocol is an outline, so the escalation rules live in the dosing plan.
Frequently Asked Questions
Phase 1 studies generally include 20 to 80 subjects and patients, per 21 CFR 312.21(a), and the regulation states the total varies with the drug. The number is not a fixed limit; it follows from how many dose levels the protocol explores and how many subjects each cohort requires.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Clinical Workflows
Track clinical trial regulations across global markets
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
